MCID: MLN069
MIFTS: 59

Melanoma, Uveal

Categories: Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Melanoma, Uveal

MalaCards integrated aliases for Melanoma, Uveal:

Name: Melanoma, Uveal 57
Uveal Melanoma 12 59 55 6 44 15 17 72
Choroidal Melanoma 59 17
Malignant Melanoma of Choroid 72
Malignant Melanoma of Iris 72
Melanoma of Uvea 12
Iris Melanoma 59

Characteristics:

Orphanet epidemiological data:

59
uveal melanoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult,elderly;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
melanoma, uveal:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:6039
OMIM 57 155720
MeSH 44 C536494
NCIt 50 C7712
MESH via Orphanet 45 C536494
ICD10 via Orphanet 34 C69.3
UMLS via Orphanet 73 C0220633 C0346373 C0346388
Orphanet 59 ORPHA39044
MedGen 42 C0220633
UMLS 72 C0220633 C0346373 C0346388

Summaries for Melanoma, Uveal

Disease Ontology : 12 A uveal cancer that has material basis in uvea pigment cells.

MalaCards based summary : Melanoma, Uveal, also known as uveal melanoma, is related to melanoma and malignant conjunctival melanoma. An important gene associated with Melanoma, Uveal is GNA11 (G Protein Subunit Alpha 11), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Ranibizumab and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and testes, and related phenotypes are visual loss and choroidal melanoma

Wikipedia : 75 Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, or choroid... more...

More information from OMIM: 155720

Related Diseases for Melanoma, Uveal

Diseases in the Melanoma, Uveal family:

Melanoma, Uveal 1 Melanoma, Uveal 2
Posterior Uveal Melanoma

Diseases related to Melanoma, Uveal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 387)
# Related Disease Score Top Affiliating Genes
1 melanoma 32.1 PAUPAR NRAS MIRLET7B MIR193B MALAT1 CDKN2A
2 malignant conjunctival melanoma 31.7 NRAS GNAQ GNA11
3 ocular cancer 31.6 GNAQ GNA11 CDKN2A
4 skin melanoma 31.6 TYR NRAS CDKN2A
5 mucosal melanoma 31.4 NRAS GNAQ GNA11
6 melanoma, cutaneous malignant 1 31.4 NRAS GNAQ GNA11 CDKN2A BAP1
7 malignant spindle cell melanoma 31.3 TYR NRAS
8 uveal disease 31.1 GNAQ GNA11 BAP1
9 cervical cancer 30.7 MIRLET7B MIR143 MALAT1 HOXA11-AS CDKN2A
10 myeloma, multiple 30.6 NRAS MIRLET7B MALAT1 CDKN2A
11 nodular malignant melanoma 30.4 NRAS GNAQ
12 leukemia, acute myeloid 30.0 SF3B1 NRAS MIRLET7B MALAT1
13 necrotic uveal melanoma 12.6
14 mixed cell uveal melanoma 12.5
15 melanoma, uveal 1 12.5
16 melanoma, uveal 2 12.5
17 bap1 tumor predisposition syndrome 12.0
18 tumor predisposition syndrome 11.9
19 uveal epithelioid cell melanoma 11.5
20 choroid mixed cell melanoma 11.5
21 spindle cell intraocular melanoma 11.4
22 choroid necrotic melanoma 11.3
23 choroid spindle cell melanoma 11.3
24 phakomatosis cesioflammea 10.9 GNAQ GNA11
25 conjunctival cancer 10.8 NRAS GNAQ GNA11
26 melanomatosis 10.7 NRAS GNAQ GNA11 CDKN2A
27 meningeal melanomatosis 10.7 NRAS GNAQ GNA11 CDKN2A
28 meningeal melanocytoma 10.7 NRAS GNAQ GNA11 CDKN2A
29 malignant peritoneal mesothelioma 10.7 CDKN2A BAP1
30 ovarian serous carcinoma 10.7 MIRLET7B MIR143
31 nervous system cancer 10.7 GNAQ GNA11 CDKN2A
32 laryngeal squamous cell carcinoma 10.7 MALAT1 HOXA11-AS CDKN2A
33 central nervous system melanocytic neoplasm 10.7 TYR NRAS GNAQ GNA11 CDKN2A
34 acral lentiginous melanoma 10.6 NRAS CDKN2A
35 vulva squamous cell carcinoma 10.6 MALAT1 CDKN2A
36 optic nerve disease 10.6
37 severe combined immunodeficiency 10.5
38 macular retinal edema 10.5
39 yemenite deaf-blind hypopigmentation syndrome 10.4
40 chromosomal triplication 10.4
41 retinal vascular disease 10.4
42 hydrops, lactic acidosis, and sideroblastic anemia 10.3
43 breast cancer 10.3
44 keratitis, hereditary 10.3
45 47,xyy 10.3
46 macular degeneration, age-related, 1 10.3
47 chudley-mccullough syndrome 10.3
48 ocular melanoma 10.3
49 autoimmune disease 10.2
50 neurofibromatosis, type iv, of riccardi 10.2

Graphical network of the top 20 diseases related to Melanoma, Uveal:



Diseases related to Melanoma, Uveal

Symptoms & Phenotypes for Melanoma, Uveal

Human phenotypes related to Melanoma, Uveal:

59 32 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 visual loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0000572
2 choroidal melanoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0012054
3 retinal detachment 59 32 frequent (33%) Frequent (79-30%) HP:0000541
4 iris melanoma 59 32 frequent (33%) Frequent (79-30%) HP:0011524
5 ciliary body melanoma 59 32 frequent (33%) Frequent (79-30%) HP:0012055
6 vitreous hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0007902
7 mydriasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0011499
8 metamorphopsia 59 32 occasional (7.5%) Occasional (29-5%) HP:0012508
9 ocular hypertension 59 32 occasional (7.5%) Occasional (29-5%) HP:0007906
10 abnormal visual accommodation 59 32 occasional (7.5%) Occasional (29-5%) HP:0030800
11 photopsia 59 32 occasional (7.5%) Occasional (29-5%) HP:0030786
12 abnormality of refraction 59 32 occasional (7.5%) Occasional (29-5%) HP:0000539
13 inferior lens subluxation 59 32 occasional (7.5%) Occasional (29-5%) HP:0008494
14 zonular cataract 59 32 occasional (7.5%) Occasional (29-5%) HP:0010920
15 inflammatory abnormality of the eye 59 32 very rare (1%) Very rare (<4-1%) HP:0100533
16 ocular pain 59 32 very rare (1%) Very rare (<4-1%) HP:0200026
17 abnormal fundus morphology 59 Very frequent (99-80%)
18 uveal melanoma 32 HP:0007716

Symptoms via clinical synopsis from OMIM:

57
Eyes:
uveal melanoma

Misc:
most common primary intraocular malignancy
frequent loss of chromosome 3 material and additions of chromosome 8

Clinical features from OMIM:

155720

MGI Mouse Phenotypes related to Melanoma, Uveal:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.02 CDKN2A GNA11 GNAQ NRAS TYR

Drugs & Therapeutics for Melanoma, Uveal

Drugs for Melanoma, Uveal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 3 347396-82-1 459903
2
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
3
Melphalan Approved Phase 3 148-82-3 460612 4053
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3
5
Fotemustine Investigational Phase 3 92118-27-9
6 Vaccines Phase 3
7 Freund's Adjuvant Phase 3
8 Alkylating Agents Phase 3
9 Antineoplastic Agents, Alkylating Phase 3
10 Immunosuppressive Agents Phase 3
11 Angiogenesis Inhibitors Phase 3
12 Angiogenesis Modulating Agents Phase 3
13 Antineoplastic Agents, Immunological Phase 3
14 Mitogens Phase 3
15 Endothelial Growth Factors Phase 3
16 Liver Extracts Phase 3
17
Sodium citrate Approved, Investigational Phase 2 68-04-2
18
Tamoxifen Approved Phase 2 10540-29-1 2733526
19
Tramadol Approved, Investigational Phase 1, Phase 2 27203-92-5 33741
20
Ibuprofen Approved Phase 1, Phase 2 15687-27-1 3672
21
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
22 Ethiodized oil Approved, Investigational Phase 2 8008-53-5
23
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
24
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
25
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
26
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
27
Pasireotide Approved Phase 2 396091-73-9 9941444
28
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
29
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
30
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
31
Aluminum sulfate Approved Phase 2 10043-01-3
32
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
33
Pancrelipase Approved, Investigational Phase 2 53608-75-6
34
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
35
Acyclovir Approved Phase 2 59277-89-3 2022
36
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
37
Olaparib Approved Phase 2 763113-22-0 23725625
38
Iodine Approved, Investigational Phase 2 7553-56-2 807
39
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
40
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
43
Cobalt Approved, Experimental Phase 2 7440-48-4 104729
44
Acetaminophen Approved Phase 2 103-90-2 1983
45
Promethazine Approved, Investigational Phase 2 60-87-7 4927
46
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
47
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
48
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
49
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
50
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4

Interventional clinical trials:

(show top 50) (show all 151)
# Name Status NCT ID Phase Drugs
1 A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma Unknown status NCT00540930 Phase 4 Ranibizumab
2 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
3 Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma. Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
4 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
5 A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
6 Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma Completed NCT00680225 Phase 3 Ranibizumab injection and TTT - ICG based
7 A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
8 A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma Completed NCT01989572 Phase 3
9 A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA Recruiting NCT01983748 Phase 3
10 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
11 A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma Recruiting NCT02678572 Phase 3
12 Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
13 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
14 Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
15 Phase II Single-Center Study of Bevacizumab in Combination With Temozolomide in Patients With First-Line Metastatic Uveal Melanoma Unknown status NCT01217398 Phase 2 temozolomide
16 A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Unknown status NCT01551459 Phase 2 Dacarbazine;Sunitinib
17 A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
18 A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
19 A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma Unknown status NCT02936388 Phase 2
20 Post-Operative Pain Relief Following Insertion of Radioactive Plaque for Choroidal Melanoma: Randomised Control Trial of Tramadol Vs Ibuprofen: A Pilot Study Unknown status NCT00111046 Phase 1, Phase 2 Ibuprofen;Tramadol
21 A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma Completed NCT00738361 Phase 2 nab-paclitaxel
22 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
23 Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
24 A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma Completed NCT02363283 Phase 2 Glembatumumab Vedotin
25 Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Completed NCT00661622 Phase 2 GM-CSF
26 A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma Completed NCT00506142 Phase 2 Marqibo® (vincristine sulfate liposomes injection)
27 Phase II Study of IMC-A12 in Metastatic Uveal Melanoma Completed NCT01413191 Phase 2
28 A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
29 A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
30 Open Label Phase II Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
31 Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma Completed NCT00089206 Phase 2
32 A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
33 Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
34 Phase II Study of Pegylated Interferon and Thalidomide in Pretreated Metastatic Malignant Melanoma Completed NCT00238329 Phase 2 thalidomide
35 An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
36 Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma Completed NCT00089219 Phase 1, Phase 2
37 A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
38 A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
39 A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma Completed NCT00031733 Phase 2 alum adjuvant
40 An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
41 A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide
42 Study of the Modulatory Activity of an LHRH-Agonist (Leuprolide) on Melanoma Peptide Vaccines as Adjuvant Therapy in Melanoma Patients Completed NCT00254397 Phase 2 Leuprolide
43 Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma Completed NCT01251978 Phase 2 Ranibizumab 2 mg;0.5 mg Ranibizumab
44 MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma Completed NCT00058279 Phase 1, Phase 2
45 Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance Completed NCT01100528 Phase 2 dacarbazine
46 Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Treatment of Patients With Metastatic Uveal (Choroidal) Malignant Melanoma Completed NCT00244816 Phase 2 Taxoprexin
47 Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma Completed NCT00085306 Phase 2
48 A Phase II Study of AZD2171 in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma Completed NCT00243061 Phase 2 cediranib maleate
49 A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients With Recurrent Inoperable Stage III or Stage IV Melanoma Completed NCT00450255 Phase 2
50 A Randomized Phase II Trial of a Vaccine Combining Tyrosinase/gp100 Peptides Emulsified With Montanide ISA 51 With and Without Interleukin-12 for Patients With Resected Stages III and IV Melanoma Completed NCT00003339 Phase 2

Search NIH Clinical Center for Melanoma, Uveal

Cochrane evidence based reviews: uveal melanoma

Genetic Tests for Melanoma, Uveal

Anatomical Context for Melanoma, Uveal

MalaCards organs/tissues related to Melanoma, Uveal:

41
Eye, Liver, Testes, Endothelial, T Cells, Retina, Bone

Publications for Melanoma, Uveal

Articles related to Melanoma, Uveal:

(show top 50) (show all 3431)
# Title Authors PMID Year
1
Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi. 9 38 8
17207529 2007
2
Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy. 9 38 8
17325166 2007
3
Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. 9 38 8
12556369 2003
4
Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. 9 38 8
11773005 2002
5
Angiostatin produced by certain primary uveal melanoma cell lines impedes the development of liver metastases. 9 38 8
11735791 2001
6
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. 38 8
23793026 2013
7
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. 38 8
23313955 2013
8
What hope for the future? GNAQ and uveal melanoma. 38 8
21378004 2011
9
Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma. 38 8
20819828 2011
10
Frequent mutation of BAP1 in metastasizing uveal melanomas. 38 8
21051595 2010
11
Mutations in GNA11 in uveal melanoma. 38 8
21083380 2010
12
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. 38 8
19078957 2009
13
Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. 38 8
18172070 2008
14
Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. 38 8
17386288 2007
15
Geographic disparities in diagnostic screening for metastatic uveal melanoma. 38 8
15582082 2004
16
Noninvasive in vivo detection of prognostic indicators for high-risk uveal melanoma: ultrasound parameter imaging. 38 8
15019336 2004
17
Liver function tests in metastatic uveal melanoma. 38 8
14962411 2004
18
Histopathology of eyes enucleated after endoresection of choroidal melanoma. 38 8
14711728 2004
19
Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. 38 8
14691146 2004
20
Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. 38 8
12766034 2003
21
Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. 38 8
12766035 2003
22
EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. 38 8
12714608 2003
23
Incidence of uveal melanoma in the United States: 1973-1997. 38 8
12750097 2003
24
Tumor basal area and metastatic death after proton beam irradiation for choroidal melanoma. 38 8
12523887 2003
25
Efficacy of (123)N-isopropyl-p-[(123)I]-iodoamphetamine single photon emission computed tomography for the diagnosis of uveal malignant melanoma. 38 8
11730669 2001
26
Calcification in choroidal melanoma after transpupillary thermotherapy. 38 8
11730670 2001
27
Uveal melanoma: no expression of HLA-G. 38 8
11726606 2001
28
Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. 38 8
11309305 2001
29
Concurrent choroidal melanoma in son and father. 38 8
11078855 2000
30
Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. 38 8
10922199 2000
31
Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. 38 8
10922203 2000
32
Occurrence of retinoblastoma and uveal melanoma in the same patient. 38 8
10872940 2000
33
Familial uveal melanoma. Clinical observations on 56 patients. 38 8
8602775 1996
34
Two subclones in a case of uveal melanoma. Relevance of monosomy 3 and multiplication of chromosome 8q. 38 8
7954325 1994
35
Familial uveal melanoma. 38 8
8154536 1994
36
The prognostic value of tumor blood vessel morphology in primary uveal melanoma. 38 8
8371929 1993
37
Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma. 38 8
1384670 1992
38
Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. 38 8
1382562 1992
39
Chromosomal aberrations defining uveal melanoma of poor prognosis. 38 8
1347396 1992
40
Familial uveal melanoma. 38 8
3288276 1988
41
Loss of alleles at polymorphic loci on chromosome 2 in uveal melanoma. 38 8
3006911 1986
42
Germline mutations in BAP1 predispose to melanocytic tumors. 8
21874003 2011
43
Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. 8
20805136 2011
44
Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. 38 88
18477892 2008
45
Histopathology of documented growth in small melanocytic choroidal tumors. 8
15596595 2004
46
The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. 8
15629284 2004
47
Melanocytomas of the optic disk. 8
15629287 2004
48
Melanocytoma of optic disc in 115 cases: the 2004 Samuel Johnson Memorial Lecture, part 1. 8
15350331 2004
49
Optical coherence tomography in the evaluation of retinal changes associated with suspicious choroidal melanocytic tumors. 8
14700649 2004
50
Consecutive choroidal melanoma in the same eye of a patient. 8
12719093 2003

Variations for Melanoma, Uveal

ClinVar genetic disease variations for Melanoma, Uveal:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PLCB4 NM_001172646.1(PLCB4): c.1924G> T (p.Asp642Tyr) single nucleotide variant Pathogenic 20:9389753-9389753 20:9409106-9409106
2 BAP1 NM_004656.4(BAP1) deletion Pathogenic 3:52439282-52439318 3:52405266-52405302
3 GNAQ NM_002072.5(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 9:80409488-80409488 9:77794572-77794572
4 GNAQ NM_002072.5(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 9:80409488-80409488 9:77794572-77794572
5 GNA11 NM_002067.5(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 19:3118942-3118942 19:3118944-3118944
6 GNA11 NM_002067.5(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 19:3118942-3118942 19:3118944-3118944
7 GNAQ NM_002072.5(GNAQ): c.625_626delinsTT (p.Gln209Leu) indel Likely pathogenic rs1057519853 9:80409488-80409489 9:77794572-77794573
8 TMEM127 NM_017849.3(TMEM127): c.562A> G (p.Ile188Val) single nucleotide variant Uncertain significance rs762657413 2:96919701-96919701 2:96253963-96253963

Copy number variations for Melanoma, Uveal from CNVD:

7 (show all 33)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13320 1 1 124300000 Copy number Uveal melanoma
2 15978 1 120700000 121100000 Nomal NOTCH2 Uveal melanoma
3 21742 1 16100000 20300000 Nomal NBL1 Uveal melanoma
4 32197 1 34400000 46500000 Nomal MYCBP Uveal melanoma
5 32198 1 34400000 46500000 Nomal PTAFR Uveal melanoma
6 33591 1 46500000 51300000 Nomal MUTYH Uveal melanoma
7 35197 1 60900000 84700000 Nomal RPE65 Uveal melanoma
8 37517 1 9200000 12600000 Nomal MFN2 Uveal melanoma
9 166068 3 1 199501827 Copy number Uveal melanoma
10 168175 3 127700000 131500000 Loss Rho Uveal melanoma
11 170048 3 150400000 153500000 Loss MME Uveal melanoma
12 172555 3 18400000 104400000 Loss CPO Uveal melanoma
13 173444 3 193800000 199501827 Loss OPA1 Uveal melanoma
14 174743 3 32100000 43600000 Loss CTNNB1 Uveal melanoma
15 175394 3 39300000 43600000 Loss MLH1 Uveal melanoma
16 175735 3 43600000 51400000 Loss SEMA3B Uveal melanoma
17 177570 3 58500000 63700000 Loss FHIT Uveal melanoma
18 178910 3 81800000 83700000 Loss ROBO1 Uveal melanoma
19 179180 3 8700000 11500000 Loss FANCD2 Uveal melanoma
20 179181 3 8700000 11500000 Loss VHL Uveal melanoma
21 203641 6 1 170899992 Copy number Uveal melanoma
22 205639 6 130400000 131300000 Nomal CTGF Uveal melanoma
23 207759 6 160900000 164400000 Nomal IGF2R Uveal melanoma
24 209014 6 2300000 4100000 Nomal Uveal melanoma
25 209045 6 23500000 26100000 Nomal DCDC2 Uveal melanoma
26 210240 6 29900000 45200000 Nomal RUNX2 Uveal melanoma
27 212309 6 36800000 40600000 Nomal CDKN1A Uveal melanoma
28 232746 8 119200000 122500000 Gain MYC Uveal melanoma
29 233772 8 127300000 140000000 Gain DDEF1 Uveal melanoma
30 238089 8 29700000 38500000 Nomal NRG1 Uveal melanoma
31 240056 8 45200000 146274826 Copy number Uveal melanoma
32 240078 19 67920024 67921999 Gain GDF-15 Uveal melanoma
33 240624 8 52800000 55600000 Gain RP1 Uveal melanoma

Expression for Melanoma, Uveal

Search GEO for disease gene expression data for Melanoma, Uveal.

Pathways for Melanoma, Uveal

Pathways related to Melanoma, Uveal according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1 12.58 PLCB4 NRAS GNAQ GNA11 CDKN2A
2 12.15 NRAS MIRLET7B MIR193B MIR143 CDKN2A
3
Show member pathways
12.03 PLCB4 GNAQ GNA11 CYSLTR2
4 11.9 PLCB4 NRAS GNAQ
5
Show member pathways
11.84 PLCB4 GNAQ GNA11
6 11.8 PLCB4 NRAS GNAQ
7
Show member pathways
11.8 PLCB4 NRAS GNAQ GNA11
8 11.77 PLCB4 NRAS GNAQ
9 11.75 PLCB4 NRAS CDKN2A
10 11.71 PLCB4 GNAQ GNA11
11 11.66 PLCB4 GNAQ GNA11
12 11.38 PLCB4 GNAQ GNA11
13 11.2 PLCB4 NRAS GNAQ GNA11
14 11.14 PLCB4 GNAQ GNA11
15 11.04 PLCB4 GNAQ GNA11
16 10.87 PLCB4 NRAS GNAQ GNA11
17 10.86 NRAS GNAQ
18
Show member pathways
10.7 GNAQ GNA11
19 10.7 PLCB4 NRAS GNAQ GNA11

GO Terms for Melanoma, Uveal

Biological processes related to Melanoma, Uveal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 action potential GO:0001508 9.26 GNAQ GNA11
2 G protein-coupled acetylcholine receptor signaling pathway GO:0007213 9.16 GNAQ GNA11
3 phototransduction, visible light GO:0007603 8.96 GNAQ GNA11
4 entrainment of circadian clock GO:0009649 8.62 GNAQ GNA11

Molecular functions related to Melanoma, Uveal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein beta/gamma-subunit complex binding GO:0031683 9.16 GNAQ GNA11
2 guanyl nucleotide binding GO:0019001 8.96 GNAQ GNA11
3 type 2A serotonin receptor binding GO:0031826 8.62 GNAQ GNA11

Sources for Melanoma, Uveal

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....